COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy of Palatinose™ Versus Sucrose on Flow Mediated Dilation in Healthy Subjects With Mild Hypertension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03986775
Recruitment Status : Completed
First Posted : June 14, 2019
Last Update Posted : June 17, 2019
Information provided by (Responsible Party):

Brief Summary:
To determine the efficacy of Palatinose versus sucrose on Flow Mediated Dilation (FMD) in healthy subjects with mild hypertension.

Condition or disease Intervention/treatment Phase
Overweight and Obesity Dietary Supplement: isomaltulose Dietary Supplement: sucrose Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: AFCRO-066: A Double-blinded, Randomized, Controlled, Acute, Cross-over Study to Determine the Efficacy of Palatinose™ Versus Sucrose on Flow Mediated Dilation in Healthy Subjects With Mild Hypertension
Actual Study Start Date : August 1, 2016
Actual Primary Completion Date : March 3, 2017
Actual Study Completion Date : August 9, 2017

Arm Intervention/treatment
Active Comparator: citrus drink with isomaltulose Dietary Supplement: isomaltulose
replacement of sucrose with low-glycemic isomaltulose

Placebo Comparator: citrus drink with sucrose Dietary Supplement: sucrose
conventional beverage with sucrose

Primary Outcome Measures :
  1. Brachial ultrasound FMD scan [ Time Frame: Baseline, 60 minutes, 120 minutes, 180 minutes ]
    Changes in postprandial flow-mediated Dilation (endothelial function)

Secondary Outcome Measures :
  1. Postprandial glycemic response [ Time Frame: Baseline, 60 minutes, 120 minutes, 180 minutes ]
    Postprandial glycemic response (Plasma samples)

  2. Postprandial insulin response [ Time Frame: Baseline, 60 minutes, 120 minutes, 180 minutes ]
    Postprandial Insulin response (Plasma samples)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion criteria:

  • Subject is healthy at the time of pre-examination
  • Subject has a BMI of 25 - 35 kg/m²
  • Subject is aged 25 - 50 years at the time of pre-examination
  • Signed written informed consent
  • Inactive (IPAQ score <1)
  • Waist to Hip ratio ≥0.90 cm for males, ≥0.85 cm for females
  • High-normo/Mild hypertensive (SBP: 130-159 mmHg / DBP: 80-99 mmHg)

Exclusion criteria:

  • Use of medication interfering with RAAS, such as ACE-inhibitors,
  • Advanced cardio-vascular disease (CVD),
  • Severe kidney disorders (CKD),
  • Diabetes mellitus, both type 1 and II diabetes,
  • Pregnant, lactating or wish to become pregnant,
  • Hypersensitivity to any of the components of the test product,
  • Restricted diet (vegetarian)
  • Thyroid disease
  • Heavy Smokers (light smokers allowed)
  • Lack of suitability for participation in the trial, for any medical reason, as judged by the PI.
  • Excessive alcohol consumption (>21 units/week for males & >14 units/week for females)
Layout table for additonal information
Responsible Party: Beneo-Institute Identifier: NCT03986775    
Other Study ID Numbers: AFCRO-066
First Posted: June 14, 2019    Key Record Dates
Last Update Posted: June 17, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Beneo-Institute:
Glycemic Index
Endothelial function
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Cardiovascular Diseases
Body Weight
Signs and Symptoms